Flores-Dorantes MT, Diaz-Lopez YE, Gutierrez-Aguilar R. Environment and gene association with obesity and their impact on neurodegenerative and neurodevelopmental diseases. Front Neurosci. 2020;14:863.

Article  PubMed  PubMed Central  Google Scholar 

Crawford K, Bracher-Smith M, Owen D, Kendall KM, Rees E, Pardinas AF, et al. Medical consequences of pathogenic CNVs in adults: analysis of the UK Biobank. J Med Genet. 2019;56:131–8.

Article  CAS  PubMed  Google Scholar 

Owen D, Bracher-Smith M, Kendall KM, Rees E, Einon M, Escott-Price V, et al. Effects of pathogenic CNVs on physical traits in participants of the UK Biobank. BMC Genomics. 2018;19:867.

Article  PubMed  PubMed Central  Google Scholar 

Vos N, Kleinendorst L, van der Laan L, van Uhm J, Jansen PR, van Eeghen AM, et al. Evaluation of 100 Dutch cases with 16p11.2 deletion and duplication syndromes; from clinical manifestations towards personalized treatment options. Eur J Hum Genet. 2024. https://doi.org/10.1038/s41431-024-01601-2. Online ahead of print.

Walters RG, Jacquemont S, Valsesia A, de Smith AJ, Martinet D, Andersson J, et al. A new highly penetrant form of obesity due to deletions on chromosome 16p11.2. Nature. 2010;463:671–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McDonald-McGinn DM, Sullivan KE, Marino B, Philip N, Swillen A, Vorstman JA, et al. 22q11.2 deletion syndrome. Nat Rev Dis Primers. 2015;1:15071.

Article  PubMed  PubMed Central  Google Scholar 

Voll SL, Boot E, Butcher NJ, Cooper S, Heung T, Chow EW, et al. Obesity in adults with 22q11.2 deletion syndrome. Genet Med. 2017;19:204–8.

Article  CAS  PubMed  Google Scholar 

Soubry E, David K, Swillen A, Vergaelen E, Docx Op de Beeck M, Hulsmans M, et al. Endocrine manifestations in adults with 22q11.2 deletion syndrome: a retrospective single-center cohort study. J Endocrinol Invest. 2024;47:1827–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heymsfield SB, Peterson CM, Thomas DM, Heo M, Schuna JM Jr. Why are there race/ethnic differences in adult body mass index-adiposity relationships? A quantitative critical review. Obes Rev. 2016;17:262–75.

Article  CAS  PubMed  Google Scholar 

Barton BB, Segger F, Fischer K, Obermeier M, Musil R. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19:295–314.

Article  CAS  PubMed  Google Scholar 

Van L, Heung T, Malecki SL, Fenn C, Tyrer A, Sanches M, et al. 22q11.2 microdeletion and increased risk for type 2 diabetes. EClinicalMedicine. 2020;26:100528.

Article  PubMed  PubMed Central  Google Scholar 

Blagojevic C, Heung T, Malecki S, Ying S, Cancelliere S, Hegele RA, et al. Hypertriglyceridemia in young adults with a 22q11.2 microdeletion. Eur J Endocrinol. 2022;187:91–9.

Article  CAS  PubMed  Google Scholar 

Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143:e984–e1010.

Article  PubMed  PubMed Central  Google Scholar 

Neeland IJ, Ross R, Despres JP, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7:715–25.

Article  PubMed  Google Scholar 

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.

Article  CAS  PubMed  Google Scholar 

Billett J, Cowie MR, Gatzoulis MA, Vonder Muhll IF, Majeed A. Comorbidity, healthcare utilisation and process of care measures in patients with congenital heart disease in the UK: cross-sectional, population-based study with case-control analysis. Heart. 2008;94:1194–9.

Article  CAS  PubMed  Google Scholar 

Neurodevelopmental disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed: American Psychiatric Association, 2013. pp 33–38.

Nishida C, Ko GT, Kumanyika S. Body fat distribution and noncommunicable diseases in populations: overview of the 2008 WHO expert consultation on waist circumference and waist-hip ratio. Eur J Clin Nutr. 2010;64:2–5.

Article  CAS  PubMed  Google Scholar 

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.

Article  PubMed  Google Scholar 

Slagter SN, van Waateringe RP, van Beek AP, van der Klauw MM, Wolffenbuttel BHR, van Vliet-Ostaptchouk JV. Sex, BMI and age differences in metabolic syndrome: the Dutch Lifelines cohort study. Endocr Connect. 2017;6:278–88.

Article  PubMed  PubMed Central  Google Scholar 

Nigatu YT, Reijneveld SA, de Jonge P, van Rossum E, Bultmann U. The combined effects of obesity, abdominal obesity and major depression/anxiety on health-related quality of life: the LifeLines cohort study. PLoS ONE. 2016;11:e0148871.

Article  PubMed  PubMed Central  Google Scholar 

American Heart A, National Heart L, Blood I, Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev. 2005;13:322–7.

Article  Google Scholar 

Boot E, Óskarsdóttir S, Loo JCY, Crowley TB, Orchanian-Cheff A, Andrade DM, et al. Updated clinical practice recommendations for managing adults with 22q11.2 deletion syndrome. Genet Med. 2023;25:100344.

Article  CAS  PubMed  Google Scholar 

Heung T, Conroy B, Malecki S, Ha J, Boot E, Corral M, et al. Adult height, 22q11.2 deletion extent, and short stature in 22q11.2 deletion syndrome. Genes. 2022;13:2038.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanssen R, Auwerx C, Joeloo M, Sadler MC, Estonian Biobank Research T, Henning E, et al. Chromosomal deletions on 16p11.2 encompassing SH2B1 are associated with accelerated metabolic disease. Cell Rep Med. 2023;4:101155.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mefford HC, Clauin S, Sharp AJ, Moller RS, Ullmann R, Kapur R, et al. Recurrent reciprocal genomic rearrangements of 17q12 are associated with renal disease, diabetes, and epilepsy. Am J Hum Genet. 2007;81:1057–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prasun P. Mitochondrial dysfunction in metabolic syndrome. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165838.

Article  CAS  PubMed  Google Scholar 

Devaraju P, Zakharenko SS. Mitochondria in complex psychiatric disorders: Lessons from mouse models of 22q11.2 deletion syndrome: Hemizygous deletion of several mitochondrial genes in the 22q11.2 genomic region can lead to symptoms associated with neuropsychiatric disease. Bioessays. 2017;39:1600177.

Boot E, Booij J, Zinkstok J, Abeling N, de Haan L, Baas F, et al. Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome. Neuropsychopharmacology. 2008;33:1252–8.

Article  CAS  PubMed  Google Scholar 

Zinkstok JR, Boot E, Bassett AS, Hiroi N, Butcher NJ, Vingerhoets C, et al. Neurobiological perspective of 22q11.2 deletion syndrome. Lancet Psychiatry. 2019;6:951–60.

Article  PubMed  PubMed Central  Google Scholar 

Rogdaki M, Devroye C, Ciampoli M, Veronese M, Ashok AH, McCutcheon RA, et al. Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study. Mol Psychiatry. 2023;28:1995–2006.

Article  CAS  PubMed  Google Scholar 

Fulton S. Appetite and reward. Front Neuroendocrinol. 2010;31:85–103.

Article  PubMed  Google Scholar 

Volkow ND, Wise RA, Baler R. The dopamine motive system: implications for drug and food addiction. Nat Rev Neurosci. 2017;18:741–52.